Terns Pharmaceuticals Inc. experienced a significant surge in its stock price Wednesday, climbing 14% following the release of promising results from an early-stage trial concerning its chronic myeloid leukemia (CML) treatment, TERN-701. The excitement surrounding the trial data has prompted a wave of positive analyst commentary, forecasting further gains for the biopharmaceutical company.<\/p>\n
The data from the trial have impressed analysts at Mizuho, Graig Suvannavejh and Avantika Joshi, who see this as indicative of a potential “best-in-class profile” for TERN-701. Their assessment is based on both efficacy and safety\/tolerability, particularly when compared to Novartis’ Scemblix (asciminib), a third-generation allosteric tyrosine kinase inhibitor (TKI) that has quickly become a new standard of care in CML treatment since its approval in 2021.<\/p>\n
Mizuho has maintained its “outperform” rating for Terns Pharmaceuticals, equivalent to a buy recommendation. Alongside TERN-701, the company is also developing a weight-loss pill with considerable expectations attached to it. Analysts note that while the excitement over TERN-701 is palpable, the chronic myeloid leukemia market, now estimated at approximately $5 billion, offers a well-established opportunity for Terns.<\/p>\n
Even with existing options like Scemblix, there lies a crucial opportunity for Terns to improve on the efficacy, safety, tolerability, and user-friendliness of treatment options for patients in need of lifelong therapies. Mizuho\u2019s analysts are modeling TERN-701 as a second-line CML treatment. They anticipate peak risk-unadjusted sales of $2.5 billion in the U.S. and $1.2 billion in the primary European markets, including France, Germany, Italy, Spain, and the U.K., based on a 50% success probability and a potential U.S. market entry in 2030. Should Terns aim for a first-line label for TERN-701, based on the recent data, this could yield significant upside potential to current estimates.<\/p>\n
UBS analysts have echoed similar sentiments, also maintaining a buy rating on Terns. They highlighted the trial’s encouraging data, noting the absence of dose-limiting toxicities and a remarkable major molecular response rate of 50% at three months. This response rate is crucial as it reflects treatment effectiveness in CML cases. Of the 15 patients enrolled in the trial, approximately 88% showed reductions in the abnormal protein BCR-ABL, which is prevalent in most CML instances.<\/p>\n
UBS has also pointed out the importance of tolerability in CML treatments, as it significantly influences patient transitions between different therapies. Additionally, the firm maintains a positive outlook on Terns’ obesity drug, which enters an increasingly competitive field but has shown promising 28-day weight loss results comparable to existing options.<\/p>\n
Oppenheimer, holding an outperform rating on Terns, shared insights on TERN-701 being an undervalued asset. Analysts led by Jay Olson stressed that the recent data endorses development in earlier-line treatment settings, predicting strengthened long-term major molecular response data by the end of 2025 following dose expansion efforts in early 2025.<\/p>\n
Terns’ stock has surged approximately 12% year-to-date, outperforming the SPDR S&P Biotech ETF (XBI), which has seen an 11% rise, and the broader S&P 500 index that has increased by around 27%. With the recent optimism bolstered by strong clinical trial results, analysts believe Terns Pharmaceuticals is still undervalued within an aggressive biotech market landscape.<\/p>\n
As Terns Pharmaceuticals continues to innovate and present promising data for its therapies, market sentiment around its stock seems to be on an upward trajectory. With increasing analyst endorsements and a significant potential market opportunity in both oncology and obesity treatment, Terns appears poised for continued growth.<\/p>\n","protected":false},"excerpt":{"rendered":"
Terns Pharmaceuticals Inc. Stock Soars on Positive Leukemia Trial Data Terns Pharmaceuticals Inc. experienced a significant surge in its stock price Wednesday, climbing 14% following the release of promising results from an early-stage trial concerning its chronic myeloid leukemia (CML) treatment, TERN-701. The excitement surrounding the trial data has prompted a wave of positive analyst…<\/p>\n","protected":false},"author":32,"featured_media":9398,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_eb_attr":"","footnotes":""},"categories":[685],"tags":[],"class_list":["post-9399","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-stocks"],"_links":{"self":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/posts\/9399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/comments?post=9399"}],"version-history":[{"count":0,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/posts\/9399\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/media\/9398"}],"wp:attachment":[{"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/media?parent=9399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/categories?post=9399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wallstwarroom.com\/h\/wp-json\/wp\/v2\/tags?post=9399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}